Thunder Biotech is a pre-clinical, cancer-immunotherapy company that has patented innovative treatments to treat cancer. This therapy genetically engineers a patient's own immune cells (macrophages) into MOTO-CARs, which target specific biomarkers present on the surface of tumor cells. These MOTO-CARs have the ability both to identify cancer cells and to engage the patient's immune system to attack and destroy tumor cells.
This novel technology, developed by Thunder Biotech, has tremendous potential to help patients conquer cancer. With this new approach to fight an old disease, Thunder Biotech is emerging as a leader in CAR (Chimeric Antigen Receptor) macrophage immunotherapy cancer treatment.